Table 1. Disease characteristics and expression of immunohistochemical markers.
| Clinical-pathological characteristics | Number of patients (%) |
|---|---|
| Age (years) | |
| ≤65 | 409 (77.0) |
| >65 | 122 (23.0) |
| Sex | |
| Female | 325 (61.2) |
| Male | 206 (38.8) |
| Smoking status | |
| Never | 418 (78.7) |
| Ever | 113 (21.3) |
| Tumor size (cm) | |
| ≤2.0 | 271 (51.0) |
| >2.0 | 260 (49.0) |
| T stage | |
| T1 | 404 (76.1) |
| T2 | 105 (19.8) |
| T3 | 14 (2.6) |
| T4 | 8 (1.5) |
| N stage | |
| N0 | 388 (73.1) |
| N1 | 52 (9.8) |
| N2 | 91 (17.1) |
| Pathologic TNM stage | |
| I | 373 (70.2) |
| II | 61 (11.5) |
| III | 97 (18.3) |
| ECOG performance score | |
| 0-1 | 504 (94.9) |
| 2 | 27 (5.1) |
| Type of EGFR mutation | |
| L858R | 228 (42.9) |
| 19del | 244 (46.0) |
| Uncommon mutations | 59 (11.1) |
| Lymphovascular invasion | |
| Absent | 434 (81.7) |
| Present | 97 (18.3) |
| Visceral pleural invasion | |
| Absent | 436 (82.1) |
| Present | 95 (17.9) |
| Histological differentiation | |
| Well | 56 (10.5) |
| Moderate | 441 (83.1) |
| Poor | 34 (6.4) |
| Histology | |
| Adenocarcinoma | |
| Lepidic | 23 (4.3) |
| Acinar | 366 (68.9) |
| Papillary | 73 (13.8) |
| Micropapillary | 16 (3.0) |
| Solid | 38 (7.2) |
| Variant | 7 (1.3) |
| Adenosquamous | 8 (1.5) |
| Her2 | |
| − | 314 (59.1) |
| + | 217 (40.9) |
| Ki67 | |
| ≤10% | 276 (52.0) |
| >10% | 255 (48.0) |
| TTF1 | |
| − | 59 (11.2) |
| + | 472 (88.8) |
| CK20 | |
| − | 494 (93.0) |
| + | 37 (7.0) |
| CK7 | |
| − | 463 (87.2) |
| + | 68 (12.8) |
| CK5/6 | |
| − | 503 (94.7) |
| + | 28 (5.3) |
| P63 | |
| − | 401 (75.5) |
| + | 130 (24.5) |
| RRM1 | |
| − | 506 (95.3) |
| + | 25 (4.7) |
| NapsinA | |
| − | 50 (9.4) |
| + | 481 (90.6) |
| Syn | |
| − | 463 (87.2) |
| + | 68 (12.8) |
EGFR, epidermal growth factor receptor; ECOG, the Eastern Corporative Oncology Group.